Cost-effectiveness of Tocilizumab in Severe Coronavirus Disease 2019: to See or Not to See

Clin Infect Dis. 2021 Dec 6;73(11):2119-2120. doi: 10.1093/cid/ciab459.

Authors

Lauren Pischel^{1

2}, George Goshua^{3

4}

Affiliations

¹ Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, USA.
² Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
³ Section of Hematology, Yale School of Medicine, New Haven, Connecticut, USA.
⁴ Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized
COVID-19 Drug Treatment*
Cost-Benefit Analysis
Humans
SARS-CoV-2
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
tocilizumab

Grants and funding

UL1 TR001863/TR/NCATS NIH HHS/United States